[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-371240-105":59,"doc-detail-371240-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","identification-of-ttll8-potee-and-pkmyt1-as-immunogenic-cancer-associated-antigens-and-potential-immunotherapy-targets-in-ovarian-cancer","Identification of TTLL8, POTEE, and PKMYT1 as immunogenic cancer-associated antigens and potential immunotherapy targets in ovarian cancer","","Most high-grade serous ovarian cancers do not respond to current immunotherapies. To find actionable tumor antigens, immunopeptidomics was performed on an ovarian cancer cell line expressing the HLA-A02:01 haplotype, identifying TTLL8, POTEE, and PKMYT1 peptides as candidates with low normal tissue expression and increased ovarian cancer expression. Tissue microarrays evaluated TTLL8 and POTEE protein levels and links to patient outcomes, with TTLL8 associated with worse prognosis. In patient TILs, cytokine production and tetramer-positive CD8 T cell populations indicated antigen-specific responses dependent on HLA class I presentation, and antigen-pulsed cells were killed by these T cells. Results support TTLL8, POTEE, and PKMYT1 as potential targets for antigen-targeted immunotherapy in ovarian cancer.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/identification-of-ttll8-potee-and-pkmyt1-as-immunogenic-cancer-associated-antigens-and-potential-immunotherapy-targets-in-ovarian-cancer/371240/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/identification-of-ttll8-potee-and-pkmyt1-as-immunogenic-cancer-associated-antigens-and-potential-immunotherapy-targets-in-ovarian-cancer/371240.png","ImageObject",300,407,{"name":92,"@type":93},"Ivy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How were TTLL8, POTEE, and PKMYT1 identified as candidate tumor antigens?","Question",{"text":112,"@type":113},"Immunopeptidomics was performed using an ovarian cancer cell line expressing the HLA-A02:01 haplotype, then peptides were selected as candidates based on low expression in normal tissues and increased expression in ovarian cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What did tissue microarrays show about TTLL8 and POTEE in patients?",{"text":117,"@type":113},"TTLL8 protein was expressed in 56.7% of ovarian cancer and was associated with worse overall prognosis, while POTEE was expressed in 97.2% but showed no significant association with survival.",{"name":119,"@type":110,"acceptedAnswer":120},"Do patient TILs mount antigen-specific CD8 T cell responses to these targets?",{"text":121,"@type":113},"Yes. In patient TILs, increases in cytokine production and tetramer-positive populations reflected antigen-specific CD8 T cell responses that depended on antigen presentation by HLA class I.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},371240,1790463355,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","ORIGINAL RESEARCH     \nIdentification of TTLL8, POTEE, and PKMYT1 as immunogenic cancer-associated antigens and potential immunotherapy targets in ovarian cancer  \nEsen Yonca Bassoya, Remya Rajaa, Thomas E. Rubino Jr.a, Fabian Cosciab, Krista Goergenc, Paul Magtibayd, Kristina Butlerd,e, Alessandra Schmittf, Ann L. Obergc, and Marion Curtis a,e,g,h  \naDepartment of Immunology, Mayo Clinic, Phoenix, AZ, USA; bMax-Delbruck-Center for Molecular Medicine in the Helmholtz Association (MDC), Spatial Proteomics Group, Berlin, Germany; cDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA; dDepartment of Obstetricsand Gynecology, Mayo Clinic, Phoenix, AZ, USA; eCollege of Medicine and Science, Mayo Clinic, Phoenix, AZ, USA; fDivision of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ, USA; gDepartment of Cancer Biology, Mayo Clinic, Phoenix, AZ, USA; hMayo Clinic Comprehensive Cancer Center, Mayo Clinic, Phoenix, AZ, USA  \nABSTRACT  \nMost high-grade serous ovarian cancers (OC) do not respond to current immunotherapies. To identify potential new actionable tumor antigens in OC, we performed immunopeptidomics on a human OC cell line expressing the HLA-A02:01 haplotype, which is commonly expressed across many racial and ethnic groups. From this dataset, we identified TTLL8, POTEE, and PKMYT1 peptides as candidate tumor antigens with low expression in normal tissues and upregulated expression in OC. Using tissue microarrays, we assessed the protein expression of TTLL8 and POTEE and their association with patient outcomes in a large cohort of OC patients. TTLL8 was found to be expressed in 56.7% of OC and was associated with a worse overall prognosis. POTEE was expressed in 97.2% of OC patients and had no significant association with survival. In patient TILs, increases in cytokine production and tetramer-positive populations identified antigen-specific CD8 T cell responses, which were dependent on antigen presentation by HLA class I. Antigen-specific T cells triggered cancer cell killing of antigen-pulsed OC cells. These findings suggest that TTLL8, POTEE, and PKMYT1 are potential targets for the development of antigen-targeted immunotherapy in OC.  \nARTICLE HISTORY  \nReceived 29 August 2024 Revised 27 December 2024 Accepted 24 January 2025  \nKEYWORDS  \nCancer immunology; immunotherapy; ovarian cancer; tumor antigen  \nIntroduction  \nOvarian cancer (OC) is the fourth most common gynecological malignancy. The most frequently diagnosed subtype, highgrade serous ovarian cancer (OC), is also the deadliest, with a mortality rate of 70% . 1 Despite this, there has been little improvement in patient treatment outcomes, which have remained unchanged for decades. Recent breakthroughs in cancer immunotherapies that instruct a patient’s immune system to specifically target their tumors have quickly become standard of care options for many patients. Despite these promising results, immune checkpoint inhibitor therapy has only proven successful in a subset of patients, and patients with OC have not responded favorably.2–5 Other immunotherapies, including adoptive cell therapy and cancer vaccines, also continue to be ineffective treatment options for OC.  \nThe failure of immunotherapy in OC is often attributed to the relatively low mutation burden present in OC tumors, affording low numbers of neoantigens for the immune system to target.6,7 OC is thus regarded as a non-immunogenic cancer. Nevertheless, multiple publications over decades have shown a positive association between an increased number of tumor-infiltrating T cells and prolonged survival in OC.8–10 Furthermore, earlier work from our lab11 as well as others,12–14 has demonstrated that clinically relevant tumor antigens do exist in OC. Taken together, these studies indicate that the immune system is strongly involved in  \nthis disease’s biology and that patients could benefit from new immunotherapeutic strategies.  \nCancer","cbCaigCcEY0RySTu","https://ap.wps.com/l/cbCaigCcEY0RySTu","pdf",4341533,"English","# Introduction\n## Background on ovarian cancer and immunotherapy limits\n## Rationale for tumor antigens and CT antigens\n# Materials and methods\n## Immunopeptidomics workflow","[{\"question\":\"How were TTLL8, POTEE, and PKMYT1 identified as candidate tumor antigens?\",\"answer\":\"Immunopeptidomics was performed using an ovarian cancer cell line expressing the HLA-A02:01 haplotype, then peptides were selected as candidates based on low expression in normal tissues and increased expression in ovarian cancer.\"},{\"question\":\"What did tissue microarrays show about TTLL8 and POTEE in patients?\",\"answer\":\"TTLL8 protein was expressed in 56.7% of ovarian cancer and was associated with worse overall prognosis, while POTEE was expressed in 97.2% but showed no significant association with survival.\"},{\"question\":\"Do patient TILs mount antigen-specific CD8 T cell responses to these targets?\",\"answer\":\"Yes. In patient TILs, increases in cytokine production and tetramer-positive populations reflected antigen-specific CD8 T cell responses that depended on antigen presentation by HLA class I.\"}]","Identification of TTLL8, POTEE, and PKMYT1 as immunogenic cancer-associated antigens and potential immunotherapy targets in ovarian cancer | PDF",1790191601,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/75854dc1b6da70e878154cd0a92f9b46.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/25f4ad0c0172c542e098d378c166b079.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/029e5f9f6c29f3ce8af264d63c9b3903.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7c546679e48c570febdf12c39870acd1.webp",980,1306]